Company eyes ‘golden decade’

Sandoz sees a ‘golden decade’ ahead, making big bets on its biosimilar capabilities as the industry braces for a wave of patent expiries.

Under the company’s so-called Bio100 plan, Sandoz is setting the ambitious goal to establish a portfolio of more than 100 biosimilars by 2040, up substantially from the 13 it currently markets.

Alongside this, Sandoz hopes to more than double its net sales from 2025 by the mid-2030s.